Biotech Values

[mcbio]

We still haven't seen any safety data.

I assume there is safety data from earlier trials, right? Also, if there were indeed serious safety issues in Phase 3, wouldn't that have impacted the survival data and presumably negated, or diminished, the advantage for the MDV3100 arm? Finally, we are talking about late-stage prostate cancer so I would assume it would take some serious safety issues to de-rail the drug or otherwise dampen its commercial prospects relative to the competition.

If it's clean, then I think the stock still has quite a ways to go, although of course this is already a partnered asset.

They could still get an outright buyout offer from Astellas. I hate to invest on the prospects of a potential buyout, of course, since that's so unpredictable but I think I'd still be comfy taking a position given the substantial potential milestones and taking into account the fact they intend to co-promote on a drug that has a high degree of being a blockbuster in the not-too-distant future.